Rib-X Pharmaceuticals, Ligand Pharmaceuticals' partner, has commenced Phase 3 trial of a Captisol-enabled intravenous (IV) formulation of delafloxacin to treat acute bacterial skin and skin structure infections (ABSSSI).
According to the license and supply deal, Ligand has earned a $500,000 milestone payment.
Ligand executive vice president and chief operating officer Matthew Foehr said, "Rib-X is an excellent partner, and we are confident in their ability to develop this late-stage asset. Additionally, today's announcement further reinforces the strength of Ligand's business model and the depth and quality of our portfolio of over 85 partnered programs."
Delafloxacin met or exceeded primary and secondary efficacy endpoints in Phase 2b study in comparison to Zyvox, with and without aztreonam, and vancomycin, with and without aztreonam.
